-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cirtuvivint in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cirtuvivint in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cirtuvivint in Non-Small Cell Lung Cancer Drug Details: SM-08502 is...
-
Product Insights
NewB-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack...
-
Product Insights
NewTauopathies – Drugs In Development, 2024
Empower your strategies with our Tauopathies – Drugs In Development, 2024 report and make more profitable business decisions. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of tau protein into neurofibrillary or gliofibrillary tangles in the human brain. Tau protein normally stabilizes microtubules, which are essential for intracellular transport and communication. However, when tau becomes hyperphosphorylated or misfolded, it dissociates from microtubules and forms insoluble aggregates that impair neuronal function and survival. Tauopathies can present with various clinical...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...
-
Product Insights
NewTraumatic Brain Injury – Drugs In Development, 2024
Empower your strategies with our Traumatic Brain Injury – Drugs In Development, 2024 report and make more profitable business decisions. Traumatic brain injury (TBI) happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factors include age. Certain types of traumatic brain injury increase the risk of developing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cysteamine Hydrochloride in Cystinosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cysteamine Hydrochloride in Cystinosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cysteamine Hydrochloride in CystinosisDrug Details:Cysteamine chlorhydrate/mercaptamine hydrochloride (Cystadrops) is a radiation protective agent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cirtuvivint in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cirtuvivint in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cirtuvivint in Endometrial Cancer Drug Details:SM-08502 is under development for the treatment of...